Table 7.
Effect of route and administration and therapeutic drug group (BNF chapter) on severity of error (adjusted analyses)
| Therapeutic drug group (BNF chapter) | Odds of being a potentially significant rather than a minor error (IV/IM/SC) | Odds of being a potentially serious rather than a minor error (IV/IM/SC) | ||
|---|---|---|---|---|
| No | Yes | No | Yes | |
| 1. Gastrointestinal | 1.0 | 4.56 (1.71–12.2) | 1.0 | 28.63 (10.59–77.45) |
| 2. Cardiovascular | 7.6 (6.08–9.51) | 8.04 (5.34–12.09) | 16.66 (10.41–26.64) | 64.9 (37.66–111.84) |
| 3. Respiratory | 2.77 (2.19–3.52) | 2.49 (0.72–8.63) | 1.02 (0.51–2.03) | 16.78 (1.99–141.79) |
| 4. Central nervous system | 2.15 (1.8–2.56) | 0.9 (0.5–1.62) | 10.87 (6.69–17.65) | 12.57 (4.89–32.27) |
| 5. Infections | 3.04 (2.18–4.23) | 4.52 (2.74–7.46) | 11.39 (7.38–17.57) | 22.62 (13.82–37.02) |
| 6. Endocrine | 4.33 (3.42–5.49) | 1.98 (1.19–3.3) | 22.17 (15.06–32.62) | 92.84 (37.18–231.8) |
| 7. Obstetrics, gynaecology and urinary tract | – | – | ||
| 8. Malignant disease and immunosuppression | – | – | ||
| 9. Nutrition and blood | 1.48 (1.15–1.91) | 5.29 (2.12–13.19) | 1.24 (0.6–2.56) | 21.31 (6.8–66.78) |
| 10. Musculoskeletal and joint diseases | 2.91 (1.9–4.46) | 5.32 (0.9–31.25) | 6.38 (2.54–16.06) | 184.05 (33.12–1022.82) |
Data are presented as OR (95 % CI)
BNF British National Formulary, CI confidence interval, IV/IM/SC intravenous/intramuscular/subcutaneous administration route, OR odds ratio